EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cenobamate in refractory epilepsy: Overview of treatment options and practical considerations

Bettina Schmitz, Simona Lattanzi iD, Kristl Vonck iD, Reetta Kälviäinen, Lina Nashef, Elinor Ben-Menachem

Epilepsia Open · 2023-12 · 8 (4) · 1241-1255

DOI: 10.1002/epi4.12830 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Epilepsia Open, online erschienen am 03.10.2023. Verfasst von Bettina Schmitz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Epilepsy, Department for Neurology, Vivantes Humboldt-Klinikum, Berlin, Germany. Hauptthemen laut MEDLINE: Drug Resistant Epilepsy, Epilepsies, Partial. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Management of drug resistant epilepsy (DRE) represents a challenge to the treating clinician. This manuscript addresses DRE and provides an overview of treatment options, medical, surgical, and dietary. It addresses treatment strategies in polytherapy, then focuses on the role cenobamate (CNB) may play in reducing the burden of DRE while providing practical advice for its introduction. CNB is a recently approved, third generation, anti‐seizure medication (ASM), a tetrazole‐derived carbamate, thought to have a dual mechanism of action, through its effect on sodium channels as well as on GABA A receptors at a non‐benzodiazepine site. CNB, having a long half‐life, is an effective add‐on ASM in refractory focal epilepsy with a higher response rate and a higher seizure‐freedom rate than is usually seen in regulatory clinical trials. Experience post‐licensing, though still limited, supports the findings of clinical trials and is encouraging. Its spectrum of action in relation to generalized epilepsies and seizures remains to be established, and there are no data on its efficacy in monotherapy. At the time of writing, CNB has been prescribed for some 50 000 individuals with DRE and focal epilepsy. A larger number is needed to fully establish its safety profile. It should at all times be introduced slowly to minimize the risk of serious allergic drug reactions. It has clinically meaningful interactions which must be anticipated and managed to maximize tolerability and likelihood of successful treatment. Despite the above, it may well prove to be of major benefit in the treatment of many patients with drug resistant epilepsy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistant EpilepsyEpilepsies, PartialHumansAnticonvulsantsCarbamatesTetrazolesChlorophenols

Stichwörter der Autor:innen

anti-seizure medicationscenobamatedrug resistant epilepsyepilepsy polytherapyepilepsy surgeryketogenic dietneurostimulation

Substanzen

AnticonvulsantsCarbamatesTetrazolesCenobamateChlorophenols

Autor:innen und Institutionen

  • Center for Epilepsy, Department for Neurology, Vivantes Humboldt-Klinikum, Berlin, Germany.
  • Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy.
  • Department of Neurology, 4Brain, Ghent University Hospital, Gent, Belgium.
  • Kuopio Epilepsy Center, Kuopio University Hospital, Member of ERN EpiCARE, and Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
  • Neurology Department, King's College Hospital, London, UK.
  • Institution for Clinical Neuroscience, Sahlgrenska Academy, University of Goteborg, Goteborg, Sweden.

ORCID-Profile: Simona Lattanzi, Kristl Vonck

Zitieren

APA

Schmitz, B., Lattanzi, S., Vonck, K., Kälviäinen, R., Nashef, L., & Ben-Menachem, E. (2023). Cenobamate in refractory epilepsy: Overview of treatment options and practical considerations. Epilepsia Open, 8(4), 1241-1255. https://doi.org/10.1002/epi4.12830

Vancouver

Schmitz B, Lattanzi S, Vonck K, Kälviäinen R, Nashef L, Ben-Menachem E. Cenobamate in refractory epilepsy: Overview of treatment options and practical considerations. Epilepsia Open. 2023;8(4):1241-1255. doi:10.1002/epi4.12830

BibTeX
@article{Schmitz2023,
  author = {Schmitz, Bettina and Lattanzi, Simona and Vonck, Kristl and Kälviäinen, Reetta and Nashef, Lina and Ben-Menachem, Elinor},
  title = {Cenobamate in refractory epilepsy: Overview of treatment options and practical considerations},
  journal = {Epilepsia Open},
  year = {2023},
  volume = {8},
  number = {4},
  pages = {1241--1255},
  doi = {10.1002/epi4.12830}
}
Kostenlos starten →